Antibody formulations and methods

an antibody and formulation technology, applied in the field of immunology and medicine, can solve the problems of uncharacterized organ dysfunction, no currently approved treatment for al amyloidosis that directly targets potentially toxic forms,

Inactive Publication Date: 2014-10-09
PROTHENA BIOSCI LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The mechanisms by which amyloidogenic immunoglobulin light chains result in organ dysfunction are not well characterized, however, it is hypothesized that both amyloid deposits and prefibrillar aggregates may contribute to cytotoxic effects on organs observed in patients with AL amyloidosis.
There are no currently approved treatments for AL amyloidosis that directly target potentially toxic forms of the amyloidogenic proteins.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody formulations and methods
  • Antibody formulations and methods
  • Antibody formulations and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

Selection of Humanized 2A4 for the Treatment of AL Amyloidosis

[0096]An IgG1, kappa isotype antibody was prepared, which is a humanized version of murine antibody 2A4. The light chain and heavy chain sequences of representative humanized 2A4 antibodies are set forth in FIGS. 1A-1B and 3. Nucleic acids encoding the particular humanized 2A4 antibody version 3, which amino acid sequences are shown in FIG. 3, are depicted in FIGS. 4A-4B.

[0097]The parent monoclonal 2A4 antibody is directed against a neo-carboxy terminal epitope of human serum Amyloid A (sAA), resulting from cleavage of the native sAA molecule at amino acid residue 76. The murine antibody does not cross-react with IgGs or free light chain (LC) and it has shown broad isotype recognition of patient derived AL amyloid samples examined to date. 2A4 recognizes multiple forms of AL light chain amyloid including soluble multimer and insoluble deposits. In addition, the antibody has been shown to promote regression of amyloidoma i...

example 2

Dose Determination for Humanized 2A4 Antibody

[0098]Nonclinical studies in the TRIAD mouse model and the cynomolgus monkey have utilized doses of 4 and 40 mg / kg in the mouse and 10, 50, and 100 mg / kg in the monkey. Conversion to the Human Equivalent Dose (HED) on a mg / kg basis (most appropriate conversion for monoclonal antibodies due to their restriction to the vascular space) gives HEDs of 0.32 and 3.2 for the mouse and 3.2, 16, and 32 for the monkey. Based on currently available data, the NOAEL in both species is expected to be the highest dose administered. Using a mouse HED (most sensitive species due to dosing limitations) of 3.2 and a 10× safety factor, the MRSD for first in man dosing would be approximately 0.32 mg / kg. Based upon animal studies, administration to humans is begun with a dose of 0.5 mg / kg.

example 3

Preparation of the Expression Vector

[0099]For generation of the final h2A4 IgG1 HC vector the variable region of the heavy chain was isolated by PCR using the plasmid CET1019AS-hygro-h2A4VH3-Sce 4.23.07 as template. Primers used for the amplification introduced at the 5′ end of the fragments an MfeI restriction site and at the 3′ end a BlpI restriction site for subcloning. The variable region was cloned into the MfeI and BamHI digested eukaryotic expression vector pBI-61, which contains the genomic constant regions of human IgG1 of G1m(3) allotype. The resulting recombinant expression vector pBI-61 / 2A4 IgG 1-REM is 9,015 base pairs in size and carries the selectable marker dihydrofolate reductase (DHFR) from hamster under the control of the DHFR promoter and polyadenylation signal. This vector also contains the beta-lactamase gene for selection in E. coli as well as origins of replication for E. coli (ColE1 ori), SV40 (SV40 ori) and filamentous phage f1 (f1 ori). Expression of the H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.

Description

RELATED APPLICATIONS[0001]Priority is claimed to U.S. Provisional Application No. 61 / 551,406, filed 25 Oct. 2011, which is incorporated by reference herein in its entirety.TECHNICAL FIELD[0002]The invention resides in the technical fields of immunology and medicine.BACKGROUND OF THE INVENTION[0003]Amyloidosis is a general term that describes a number of diseases characterized by the existence of pathological forms of amyloid proteins, often involving extracellular deposition of protein fibrils, which form numerous “amyloid deposits” or “amyloid plaques,” which may occur in local sites or systematically. These deposits or plaques are composed primarily of a naturally occurring soluble protein or peptide, assembled into extensive insoluble deposits 10-100 μm in diameter in a variety of tissue sites. The deposits are composed of generally lateral aggregates of fibrils that are approximately 10-15 nm in diameter. Amyloid fibrils produce a characteristic apple green birefringence in pola...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/18A61K31/195A61K31/69A61K39/395
CPCC07K16/18C07K2317/14A61K31/198A61K31/195A61K31/69A61K38/07A61K39/3955A61K31/454A61K9/19A61K39/39591A61K47/183A61K47/26A61K2039/505A61P1/04A61P11/08A61P13/02A61P13/12A61P17/00A61P17/06A61P19/02A61P25/00A61P25/28A61P29/00A61P31/00A61P31/04A61P31/06A61P31/08A61P35/00A61P43/00A61P7/00A61K47/22A61K31/325C07K2317/24C07K2317/76A61K2039/545C07K2317/41C07K2317/56C07K2317/565
Inventor GARIDEL, PATRICKHENDERSON, ISAAC CRAIGKLEIN, PAMELA
Owner PROTHENA BIOSCI LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap